Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Screenshot preview · Scroll to view the full email
Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.
More emails like this
Explore other emails with shared design, campaign, or industry tags.
Novo NordiskView brand email archive
